Viatris Eyes Gilenya Generic Following ‘Unreliable’ Study Data

Firm Also Backed For Zytiga Generic By CHMP

 
• By Dean Rudge
  
Arrows_Target
Viatris has backing after missing the mark • Source: Shutterstock

More from Regulation

More from Policy & Regulation